AC Immune (ACIU) Current Deferred Revenue (2014 - 2026)
AC Immune (ACIU) posted quarterly Current Deferred Revenue of $104.7 million for Q4 2025, up 7.87% year-over-year from $97.1 million in Q4 2024, and up 3.56% quarter-over-quarter from $101.1 million in Q2 2025.
AC Immune (ACIU) Current Deferred Revenue (2014 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Current Deferred Revenue for 12 consecutive years, with $104.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Deferred Revenue rose 7.87% year-over-year to $104.7 million; the TTM figure through Dec 2025 stood at $104.7 million (up 7.87% YoY), while the FY2025 annual figure was $101.0 million, up 3.98% from the prior year.
- Current Deferred Revenue grew to $104.7 million in Q4 2025 per ACIU's latest filing, from $101.1 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $777.6 million in Q4 2021 and bottomed at $18467.3 in Q3 2024.
- Historically, Current Deferred Revenue has averaged $166.2 million across 5 years, with a median of $48.9 million in 2024.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue jumped 229626.92% — and 2022, when it plunged 99.92%.
- AC Immune's Current Deferred Revenue stood at $777.6 million in 2021, then slumped by 99.92% to $609318.9 in 2022, then surged by 25432.59% to $155.6 million in 2023, then slumped by 37.59% to $97.1 million in 2024, then grew by 7.87% to $104.7 million in 2025.
- Business Quant data shows ACIU's Current Deferred Revenue at $104.7 million in Q4 2025, $101.1 million in Q2 2025, and $97.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 113.21 Mn |
| Dec 31, 2025 | 104.73 Mn |
| Jun 30, 2025 | 101.13 Mn |
| Dec 31, 2024 | 97.09 Mn |
| Sep 30, 2024 | 18,467.32 |
| Jun 30, 2024 | 49,760.71 |
| Mar 31, 2024 | 84,780.49 |
| Dec 31, 2023 | 155.57 Mn |
| Sep 30, 2023 | 382,667.57 |
| Jun 30, 2023 | 478,235.49 |
| Mar 31, 2023 | 448,682.47 |
| Dec 31, 2022 | 609,318.86 |
| Sep 30, 2022 | 542,579.28 |
| Jun 30, 2022 | 441.27 Mn |
| Mar 31, 2022 | 288.03 Mn |
| Dec 31, 2021 | 777.59 Mn |
| Sep 30, 2021 | 167,725.88 |
| Jun 30, 2021 | 381.63 Mn |
| Mar 31, 2021 | 641.51 Mn |
| Dec 31, 2020 | 338,483.62 |